Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOOK NASDAQ:INM NASDAQ:LEXX NASDAQ:NEUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOOKHOOKIPA Pharma$1.14$1.38$0.72▼$6.68$13.90M0.8982,930 shs185,284 shsINMInMed Pharmaceuticals$2.67+1.5%$2.85$1.72▼$15.70$5.35M0.31.02 million shs53,329 shsLEXXLexaria Bioscience$0.95+8.7%$0.96$0.79▼$4.38$18.49M0.79147,787 shs392,266 shsNEUPNeuphoria Therapeutics$7.45-0.5%$6.66$2.12▼$12.55$14.01M0.535,184 shs12,813 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOOKHOOKIPA Pharma0.00%-4.20%-12.64%+47.42%-82.43%INMInMed Pharmaceuticals0.00%-2.91%+6.37%-1.84%-50.56%LEXXLexaria Bioscience0.00%+7.33%-5.45%-31.49%-67.17%NEUPNeuphoria Therapeutics0.00%-3.12%+12.54%+44.94%+744,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHOOKHOOKIPA Pharma2.8939 of 5 stars3.25.00.00.01.81.70.6INMInMed Pharmaceuticals0.1202 of 5 stars0.02.00.00.00.60.00.6LEXXLexaria Bioscience1.8074 of 5 stars3.52.00.00.00.31.70.6NEUPNeuphoria Therapeutics1.3204 of 5 stars3.50.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOOKHOOKIPA Pharma 2.33Hold$4.50294.74% UpsideINMInMed Pharmaceuticals 0.00N/AN/AN/ALEXXLexaria Bioscience 3.00Buy$5.00428.82% UpsideNEUPNeuphoria Therapeutics 3.00Buy$21.00181.88% UpsideCurrent Analyst Ratings BreakdownLatest INM, LEXX, HOOK, and NEUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOOKHOOKIPA Pharma$43.95M0.32N/AN/A$4.25 per share0.27INMInMed Pharmaceuticals$4.92M1.09N/AN/A$20.64 per share0.13LEXXLexaria Bioscience$615.92K30.02N/AN/A$0.26 per share3.64NEUPNeuphoria Therapeutics$10K1,400.60N/AN/A$15.85 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)INMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-168.87%-107.93%-82.97%9/29/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/ANEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)Latest INM, LEXX, HOOK, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HOOKHOOKIPA Pharma-$0.64N/AN/AN/AN/AN/A7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million5/20/2025Q3 2025NEUPNeuphoria Therapeutics-$0.47$6.55+$7.02$6.55N/A$15.00 million5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/12/2025Q3 2025INMInMed PharmaceuticalsN/A-$1.94N/A-$1.94N/A$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOOKHOOKIPA PharmaN/A3.613.61INMInMed Pharmaceuticals0.063.493.04LEXXLexaria BioscienceN/A3.904.24NEUPNeuphoria TherapeuticsN/A11.0111.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOOKHOOKIPA Pharma63.88%INMInMed Pharmaceuticals20.12%LEXXLexaria Bioscience13.06%NEUPNeuphoria Therapeutics15.90%Insider OwnershipCompanyInsider OwnershipHOOKHOOKIPA Pharma3.30%INMInMed Pharmaceuticals1.43%LEXXLexaria Bioscience26.40%NEUPNeuphoria Therapeutics0.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableINMInMed Pharmaceuticals102.00 million1.97 millionNot OptionableLEXXLexaria Bioscience719.56 million14.40 millionNot OptionableNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/AINM, LEXX, HOOK, and NEUP HeadlinesRecent News About These CompaniesDementia Associated with Alzheimer’s Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsightJuly 17 at 2:51 PM | finance.yahoo.comNEUP Neuphoria Therapeutics Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comNeuphoria Therapeutics Inc. (NEUP) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNeuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual MeetingMay 27, 2025 | globenewswire.comNeuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business UpdatesMay 21, 2025 | finanznachrichten.deNeuphoria Provides First Quarter 2025 Business UpdatesMay 20, 2025 | globenewswire.comNeumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuphoria Therapeutics provides review of 2024, highlights 2025 plansApril 16, 2025 | markets.businessinsider.comNeuphoria Provides a Review of 2024 and Highlights 2025 PlansApril 15, 2025 | globenewswire.comNeuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025March 3, 2025 | globenewswire.comNeuphoria Therapeutics Inc. to Receive $15M Milestone Payment from MerckFebruary 12, 2025 | globenewswire.comHere's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep goingFebruary 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINM, LEXX, HOOK, and NEUP Company DescriptionsHOOKIPA Pharma NASDAQ:HOOK$1.14 0.00 (0.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.18 +0.04 (+3.51%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.InMed Pharmaceuticals NASDAQ:INM$2.67 +0.04 (+1.52%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.66 -0.02 (-0.56%) As of 07/18/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Lexaria Bioscience NASDAQ:LEXX$0.95 +0.08 (+8.68%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.93 -0.01 (-1.32%) As of 07/18/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Neuphoria Therapeutics NASDAQ:NEUP$7.45 -0.04 (-0.53%) As of 07/18/2025 03:55 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
